Citations

Clear

3942 citation(s) found for "To, Van".

Deep brain stimulation for orthostatic tremor
Hewitt, Angela , Klassen, Bryan T. , Lee, Kendall H. , Hassan, Anhar , Hewitt, Angela L, Hewitt, Angela L , Gompel, Jamie J. Van

Mayo Clinic

Neurology Clinical Practice | January 6, 2020 | Volume: 10 | Issue: 4 | Pages: 324-332

10.1212/cpj.0000000000000730 | PMID 32983612 Get It

Wound infection caused by Branhamella catarrhalis
Gray, L D, Scoy, Robert E. Van, Anhalt, John P., Yu, P K

Mayo Clinic

Journal of Clinical Microbiology | January 5, 2020 | Volume: 27 | Issue: 5 | Pages: 818-820

10.1128/jcm.27.5.818-820.1989 | PMID 2501347 Get It

Branhamella catarrhalis was isolated from sputum, tracheal secretions, and a nonhealing and infected thoracic surgical wound in a 59-year-old woman who had a history of a chronic, interstitial fibrosis and who had undergone an open lung biopsy procedure. The patient's upper respiratory tract was the likely source of the organism. To our knowledge, this is the first report of a wound infection caused by B. catarrhalis.
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab
Keung, Emily Z. , Salazar, Ruth , Rodrigues-Canales, Jaime, Bolejack, Vanessa , Tine, Brian A. Van , Schuetze, Scott M. , Attia, Steven , Riedel, Richard F. , Hu, James , Okuno, Scott H. , Priebat, Dennis A., Movva, Sujana , Davis, Lara E. , Wang, Wei‐Lien , Wargo, Jennifer A. , Tawbi, Hussein A. , Bolejack, Vanessa , Van Tine, Brian A , Schuetze, Scott M , Riedel, Richard F , Okuno, Scott , Davis, Lara E , Reed, Damon R , Reuben, Alexandre , Lazar, Alexander J , Burgess, Melissa , Parra, Edwin Roger , Reed, Damon R. , Roland, Christina Lynn , Reinke, Denise K. , Lazar, Alexander J.

Mayo Clinic

Clinical Cancer Research | January 3, 2020 | Volume: 26 | Issue: 6 | Pages: 1258-1266

10.1158/1078-0432.ccr-19-1824 | PMID 31900276 Get It

Abstract Purpose: We recently reported a 17.5% objective RECIST 1.1 response rate in a phase II study of pembrolizumab in patients with advanced sarcoma (SARC028). The majority of responses occurred in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). We sought to determine whether we can identify immune features that correlate with clinical outcomes from tumor tissues obtained pre- and on-treatment. Patients and Methods: Pretreatment (n = 78) and 8-week on-treatment (n = 68) tumor biopsies were stained for PD-L1 and multiplex immunofluorescence panels. The density of positive cells was quantified to determine associations with anti–PD-1 response. Results: Patients that responded to pembrolizumab were more likely to have higher densities of activated T cells (CD8+ CD3+ PD-1+) and increased percentage of tumor-associated macrophages (TAM) expressing PD-L1 pre-treatment compared with non-responders. Pre-treatment tumors from responders also exhibited higher densities of effector memory cytotoxic T cells and regulatory T cells compared with non-responders. In addition, higher density of cytotoxic tumor-infiltrating T cells at baseline correlated with a better progression-free survival (PFS). Conclusions: We show that quantitative assessments of CD8+ CD3+ PD-1+ T cells, percentage of TAMs expressing PD-L1, and other T-cell densities correlate with sarcoma response to pembrolizumab and improved PFS. Our findings support that multiple cell types present at the start of treatment may enhance tumor regression following anti–PD-1 therapy in specific advanced sarcomas. Efforts to confirm the activity of pembrolizumab in an expansion cohort of patients with UPS/DDLPS are underway.
Stroke Prophylaxis in Patients with Atrial Fibrillation and End-Stage Renal Disease
Zyl, Martin van , Abdullah, Hafez Mohammad Ammar , Siontis, Konstantinos C. , Van Zyl, Martin, Noseworthy, Peter A.

Mayo Clinic

Journal of Clinical Medicine | January 3, 2020 | Volume: 9 | Issue: 1 | Pages: 123

10.3390/jcm9010123 | PMID 31906546 Get It

Atrial fibrillation (AF) is an important comorbidity in patients with end-stage renal disease (ESRD) undergoing dialysis that portends increased health care utilization, morbidity, and mortality in this already high-risk population. Patients with ESRD have a particularly high stroke risk, which is further compounded by AF. However, the role of anticoagulation for stroke prophylaxis in ESRD and AF is debated. The ESRD population presents a unique challenge because of the combination of elevated stroke and bleeding risks. Warfarin has been traditionally used in this population, but it is associated with significant risks of minor and major bleeding, particularly intracranial, thus leading many clinicians to forgo anticoagulation altogether. When anticoagulation is prescribed, rates of adherence and persistence are poor, leaving many patients untreated. The direct oral anticoagulants (DOACs) may offer an alternative to warfarin in ESRD patients, but these agents have not been extensively studied in this population and uncertainties regarding comparative effectiveness (versus warfarin, each other, and no treatment) remain. In this review, we discuss the current evidence on the risk and benefits of anticoagulants in this challenging population and comparisons between warfarin and DOACs, and review future directions including options for non-pharmacologic stroke prevention.
Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS
Goyal, Namita , Windebank, Anthony J. , Staff, Nathan P. , Maragakis, Nicholas J. , Berg, Leonard H. van den , Genge, Angela , Baloh, Robert H. , Kern, R. , Gothelf, Yaël, Lebovits, Chaim, Cudkowicz, Merit , Windebank, Anthony, Staff, Nathan P , Maragakis, Nicholas , Cudkowicz, Merit E , Berry, James D. , Miller, Robert G.

Mayo Clinic

Muscle & Nerve | January 3, 2020 | Volume: 62 | Issue: 2 | Pages: 156-166

10.1002/mus.26801 | PMID 31899540 Get It

Abstract Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disorder with complex biology and significant clinical heterogeneity. Many preclinical and early phase ALS clinical trials have yielded promising results that could not be replicated in larger phase 3 confirmatory trials. One reason for the lack of reproducibility may be ALS biological and clinical heterogeneity. Therefore, in this review, we explore sources of ALS heterogeneity that may reduce statistical power to evaluate efficacy in ALS trials. We also review efforts to manage clinical heterogeneity, including use of validated disease outcome measures, predictive biomarkers of disease progression, and individual clinical risk stratification. We propose that personalized prognostic models with use of predictive biomarkers may identify patients with ALS for whom a specific therapeutic strategy may be expected to be more successful. Finally, the rapid application of emerging clinical and biomarker strategies may reduce heterogeneity, increase trial efficiency, and, in turn, accelerate ALS drug development.
A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer
Zhong, Jun, Jermusyk, Ashley , Wu, Lang , Hoskins, Jason W. , Collins, Irene , Mocci, Evelina , Song, Lei , Chung, Charles C., Xiao, Wenming , Andreotti, Gabriella , Arslan, Alan A. , Babić, Ana , Berndt, Sonja, Borgida, Ayelet , Bracci, Paige M. , Brennan, Paul , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Childs, Erica J., Du, Mengmeng , Fuchs, Charles S. , Gallinger, Steven , Gaziano, J. Michael, Giovannucci, Edward L. , Goodman, Gary E. , Goodman, Phyllis J. , Haiman, Christopher, Hartge, Patricia, Hasan, Manal , Helzlsouer, Kathy J., Holly, Elizabeth A., Klein, Eric A. , Kogevinas, Manolis, Kurtz, Robert J., Ng, Kimmie , Obazee, Ofure , Oberg, Ann L. , Patel, Alpa V. , Peters, Ulrike , Porta, Miquel , Rothman, Nathaniel , Scélo, Ghislaine , Sesso, Howard D. , Sieri, Sabina , Tjønneland, Anne , Thornquist, Mark, Trichopoulou, Antonia , Visvanathan, Kala , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Yuan, Chen , Zeleniuch‐Jacquotte, Anne , Hoover, Robert N. , Brown, Kevin M. , Jacobs, Eric J. , Li, Donghui , Yu, Kai , Wolpin, Brian M. , Chatterjee, Nilanjan , Shi, Jianxin , Petersen, Gloria M. , Zhong, Jun , Arslan, Alan A , Tjønneland, Anne , Wactawski-Wende, Jean , Visvanathan, Kala , Klein, Eric A , Porta, Miquel , Zeleniuch-Jacquotte, Anne , Zhong, Jun , Yuan, Chen , Hoskins, Jason W , Zhang, Mingfeng , Zhang, Tongwu , Albanes, Demetrius , Bamlet, William R. , Freeman, Laura E. Beane , Brais, Lauren K , Canzian, Federico , Cotterchio, Michelle , Duell, Eric J. , Giles, Graham G. , Goggins, Michael , Marchand, Loı̈c Le , Malats, Núria , Männistö, Satu , Milne, Roger L. , Neale, Rachel Ε. , Orlow, Irene , Rothman, Nathaniel , Severi, Gianluca , Silverman, Debra T. , Sund, Malin , Tobias, Geoffrey S. , Van Den Eeden, Stephen K , White, Emily , Yu, Kai , Kooperberg, Charles , Risch, Harvey A. , Shu, Xiao‐Ou , Chanock, Stephen Jacob , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Smith, Jill Palmer , Kraft, Peter , Zheng, Wei , Ámundadóttir, Laufey T.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | December 31, 2019 | Volume: 112 | Issue: 10 | Pages: 1003-1012

10.1093/jnci/djz246 | PMID 31917448 Get It

Abstract Background Although 20 pancreatic cancer susceptibility loci have been identified through genome-wide association studies in individuals of European ancestry, much of its heritability remains unexplained and the genes responsible largely unknown. Methods To discover novel pancreatic cancer risk loci and possible causal genes, we performed a pancreatic cancer transcriptome-wide association study in Europeans using three approaches: FUSION, MetaXcan, and Summary-MulTiXcan. We integrated genome-wide association studies summary statistics from 9040 pancreatic cancer cases and 12 496 controls, with gene expression prediction models built using transcriptome data from histologically normal pancreatic tissue samples (NCI Laboratory of Translational Genomics [n = 95] and Genotype-Tissue Expression v7 [n = 174] datasets) and data from 48 different tissues (Genotype-Tissue Expression v7, n = 74–421 samples). Results We identified 25 genes whose genetically predicted expression was statistically significantly associated with pancreatic cancer risk (false discovery rate < .05), including 14 candidate genes at 11 novel loci (1p36.12: CELA3B; 9q31.1: SMC2, SMC2-AS1; 10q23.31: RP11-80H5.9; 12q13.13: SMUG1; 14q32.33: BTBD6; 15q23: HEXA; 15q26.1: RCCD1; 17q12: PNMT, CDK12, PGAP3; 17q22: SUPT4H1; 18q11.22: RP11-888D10.3; and 19p13.11: PGPEP1) and 11 at six known risk loci (5p15.33: TERT, CLPTM1L, ZDHHC11B; 7p14.1: INHBA; 9q34.2: ABO; 13q12.2: PDX1; 13q22.1: KLF5; and 16q23.1: WDR59, CFDP1, BCAR1, TMEM170A). The association for 12 of these genes (CELA3B, SMC2, and PNMT at novel risk loci and TERT, CLPTM1L, INHBA, ABO, PDX1, KLF5, WDR59, CFDP1, and BCAR1 at known loci) remained statistically significant after Bonferroni correction. Conclusions By integrating gene expression and genotype data, we identified novel pancreatic cancer risk loci and candidate functional genes that warrant further investigation.
Absence of VEGFR‐1/Flt‐1 signaling pathway in mice results in insensitivity to discogenic low back pain in an established disc injury mouse model
Qiu, Sujun , Shi, Changgui , Anbazhagan, Arivarasu Natarajan , Das, Vaskar, Arora, Vipin , Kc, Ranjan , O‐Sullivan, InSug , Wijnen, André J. van , Chintharlapalli, Sudhakar , Gott‐Velis, Gina, Richard, Ripper, Mwale, Fackson , Shibuya, Masabumi , Min, Shaoxiong , Im, Hee‐Jeong , van Wijnen, Andre J , Li, Xin

Mayo Clinic

Journal of Cellular Physiology | December 25, 2019 | Volume: 235 | Issue: 6 | Pages: 5305-5317

10.1002/jcp.29416 | PMID 31875985 Get It

Abstract Although degenerative disc disease (DDD) and related low back pain (LBP) are growing public health problems, the underlying disease mechanisms remain unclear. An increase in the vascular endothelial growth factor (VEGF) levels in DDD has been reported. This study aimed to examine the role of VEGF receptors (VEGFRs) in DDD, using a mouse model of DDD. Progressive DDD was induced by anterior stabbing of lumbar intervertebral discs in wild type (WT) and VEGFR‐1 tyrosine‐kinase deficient mice ( vegfr‐1 TK−/ − ). Pain assessments were performed weekly for 12 weeks. Histological and immunohistochemical assessments were made for discs, dorsal root ganglions, and spinal cord. Both vegfr‐1 TK − / − and WT mice presented with similar pathological changes in discs with an increased expression of inflammatory cytokines and matrix‐degrading enzymes. Despite the similar pathological patterns, vegfr‐1 TK − / − mice showed insensitivity to pain compared with WT mice. This insensitivity to discogenic pain was related to lower levels of pain factors in the discs and peripheral sensory neurons and lower spinal glial activation in the vegfr‐1 TK − / − mice than in the WT mice. Exogenous stimulation of bovine disc cells with VEGF increased inflammatory and cartilage degrading enzyme. Silencing vegfr‐1 by small‐interfering‐RNA decreased VEGF‐induced expression of pain markers, while silencing vegfr‐2 decreased VEGF‐induced expression of inflammatory and metabolic markers without changing pain markers. This suggests the involvement of VEGFR‐1 signaling specifically in pain transmission. Collectively, our results indicate that the VEGF signaling is involved in DDD. Particularly, VEGFR‐1 is critical for discogenic LBP transmission independent of the degree of disc pathology.
Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate
Gandhi, Jatin , Smith, Steven C. , Paner, Gladell P. , McKenney, Jesse K. , Sekhri, Radhika , Osunkoya, Adeboye O. , Baras, Alexander S. , Cheville, John C. , Jiménez, Rafael E. , Trpkov, Kiril , Colecchia, Maurizio , Ro, Jae Y. , Montironi, Rodolfo , Hes, Ondřej , Hirsch, Michelle S. , Netto, George J. , Fine, Samson W. , Sirohi, Deepika , Kaushal, Seema , Robinson, Brian D. , Kweldam, Charlotte F. , Humphrey, Peter A. , Hansel, Donna E. , Schultz, Luciana , Przybycin, Christopher G. , Mehra, Rohit , Kunju, Lakshmi P., Aron, Manju , Kuroda, Naoto , Tavora, Fabio, Grignon, David J. , Epstein, Jonathan I. , Reuter, Victor E. , Amin, Mahul B. , Távora, Fábio , Robinson, Brian D. , Trpkov, Kiril , Marzo, Angelo M. De , Menon, Santosh , Williamson, Sean R. , Sangoi, Ankur R. , Magi‐Galluzzi, Cristina , Shah, Rajal B. , Kryvenko, Oleksandr N. , Kench, James G. , Kwast, Theodorus van der

Mayo Clinic

American Journal of Surgical Pathology | December 24, 2019 | Volume: 44 | Issue: 5 | Pages: 673-680

10.1097/pas.0000000000001417 | PMID 31876580 Get It

Intraductal carcinoma of the prostate (IDC-P) has been recently recognized by the World Health Organization classification of prostatic tumors as a distinct entity, most often occurring concurrently with invasive prostatic adenocarcinoma (PCa). Whether documented admixed with PCa or in its rare pure form, numerous studies associate this entity with clinical aggressiveness. Despite increasing clinical experience and requirement of IDC-P documentation in protocols for synoptic reporting, the specifics of its potential contribution to assessment of grade group (GG) and cancer quantitation of PCa in both needle biopsies (NBx) and radical prostatectomy (RP) specimens remain unclear. Moreover, there are no standard guidelines for incorporating basal cell marker immunohistochemistry (IHC) in the diagnosis of IDC-P, either alone or as part of a cocktail with AMACR/racemase. An online survey containing 26 questions regarding diagnosis, reporting practices, and IHC resource utilization, focusing on IDC-P, was undertaken by 42 genitourinary subspecialists from 9 countries. The degree of agreement or disagreement regarding approaches to individual questions was classified as significant majority (>75%), majority (51% to 75%), minority (26% to 50%) and significant minority (≤25%). IDC-P with or without invasive cancer is considered a contraindication for active surveillance by the significant majority (95%) of respondents, although a majority (66%) also agreed that the clinical significance/behavior of IDC-P on NBx or RP with PCa required further study. The majority do not upgrade PCa based on comedonecrosis seen only in the intraductal component in NBx (62%) or RP (69%) specimens. Similarly, recognizable IDC-P with GG1 PCa was not a factor in upgrading in NBx (78%) or RP (71%) specimens. The majority (60%) of respondents include readily recognizable IDC-P in assessment of linear extent of PCa at NBx. A significant majority (78%) would use IHC to confirm or exclude intraductal carcinoma if other biopsies showed no PCa, while 60% would use it to confirm IDC-P with invasive PCa in NBx if it would change the overall GG assignment. Nearly half (48%, a minority) would use IHC to confirm IDC-P for accurate Gleason pattern 4 quantitation. A majority (57%) report the percentage of IDC-P when present, in RP specimens. When obvious Gleason pattern 4 or 5 PCa is present in RP or NBx, IHC is rarely to almost never used to confirm the presence of IDC-P by the significant majority (88% and 90%, respectively). Most genitourinary pathologists consider IDC-P to be an adverse prognostic feature independent of the PCa grade, although recommendations for standardization are needed to guide reporting of IDC-P vis a vis tumor quantitation and final GG assessment. The use of IHC varies widely and is performed for a multitude of indications, although it is used most frequently in scenarios where confirmation of IDC-P would impact the GG assigned. Further study and best practices recommendations are needed to provide guidance with regards to the most appropriate indications for IHC use in scenarios regarding IDC-P.
Functional Analysis of the SIM1 Variant p.G715V in 2 Patients With Obesity
Blackburn, Patrick R. , Sullivan, Adrienne E. , Gerassimou, Alexis G , Kleinendorst, Lotte , Bersten, David C. , Cooiman, Mellody I. , Harris, Kimberly G., Wierenga, Klaas J. , Klee, Eric W. , Gerpen, Jay A. van, Ross, Owen A. , Haelst, Mieke M. van , Whitelaw, Murray L. , Caulfield, Thomas R. , Van Gerpen, Jay A, Caulfield, Thomas R , Ross, Owen A , Atwal, Paldeep S

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 24, 2019 | Volume: 105 | Issue: 1 | Pages: 355-361

10.1210/clinem/dgz192 | PMID 31872862 Get It

Abstract Context Single-minded homologue 1 (SIM1) is a transcription factor with several physiological and developmental functions. Haploinsufficiency of SIM1 is associated with early-onset obesity with or without Prader-Willi–like (PWL) features and may exhibit incomplete penetrance. Case Description Next-generation sequencing was performed for 2 male patients with obesity, including 1 man presenting with intellectual disability (ID), body mass index (BMI) of 47.4, and impulse-control disorder, and the other man with early obesity (BMI of 36); sequencing revealed a missense variant in SIM1 (c.2144G>T; p.G715V) in both individuals. Previous studies have identified several disease-associated variants that fall near the p.G715V variant within the C-terminal domain of SIM1. We examined p.G715V variant stability and activity in a doxycycline-inducible stable cell line transfected with an artificial reporter construct and either ARNT or ARNT2 as a partner protein. Conclusions Functional testing of the p.G715V variant revealed a significant reduction in SIM1-mediated transcriptional activity. We also generated the first ab initio hybrid protein model for full-length SIM1 to show the predicted spatial relationship between p.G715V and other previously described variants in this region and identified a putative mutation hotspot within the C-terminus. Significant clinical heterogeneity has been observed in patients with SIM1 variants, particularly with regards to the PWL phenotype. In the patient with ID, a second variant of uncertain significance in CHD2 was identified that may contribute to his ID and behavioral disturbances, emphasizing the role of additional genetic modifiers.
Authors' Reply
Rule, Andrew D. , Jager, Kitty J. , Delanaye, Pierre , Delanaye, Pierre , Rule, Andrew D , Jager, Kitty J , Brand, Jan A.J.G. van den

Mayo Clinic

Journal of the American Society of Nephrology | December 23, 2019 | Volume: 31 | Issue: 2 | Pages: 448-449

10.1681/asn.2019111188 | PMID 31871273 Get It